Medical AI Platform OpenEvidence Soars to $12 Billion Valuation

In a remarkable show of investor confidence, OpenEvidence - the clinical decision support platform often called the "doctor's ChatGPT" - has secured another $250 million in funding, pushing its valuation to an impressive $12 billion. This latest cash injection comes just months after its previous funding round, highlighting the breakneck pace of growth in medical AI.

What Makes OpenEvidence Special?

The platform has become indispensable for physicians by offering three key benefits:

• Instant access to peer-reviewed medical evidence with full traceability
• Real-time decision support at the point of care
• Free access for registered doctors (revenue comes from pharma ads and medical partnerships)

With 40% of U.S. physicians already using the platform and processing millions of monthly consultations, OpenEvidence's revenue has tripled since August to $150 million annually - all while maintaining enviable 90% gross margins.

From Startup to Unicorn in Record Time

The company's funding trajectory tells a compelling story:

• February 2025: $75 million Series A ($1B valuation)
• July 2025: $210 million Series B ($3.5B valuation)
• October 2025: $200 million Series C ($6B valuation)
• December 2025: $250 million latest round ($12B valuation)

This exponential growth reflects investors' belief that specialized AI applications like OpenEvidence can transform healthcare delivery.

Meanwhile in China: Ant Group Pivots to Health Companionship

Not to be outdone, Ant Group has rebranded its health AI product as "Ant Afu," shifting from pure diagnostics to comprehensive health management. The upgraded platform now offers:

• Personalized health tracking via wearable integration
• AI-powered Q&A with tailored medical advice
• Integrated services including appointment booking and remote care

With 15 million monthly active users answering over 5 million health questions daily, Ant Afu has become China's dominant health AI application - particularly successful in smaller cities and rural areas.

The Future Looks Healthy for Medical AI

The simultaneous success of these two approaches - OpenEvidence's physician-focused tools and Ant Afu's consumer health platform - demonstrates the vast potential for AI across healthcare ecosystems worldwide.

Key Points:

• OpenEvidence hits $12B valuation after $250M funding round
• Platform serves 40% of U.S. doctors with clinical decision support
• Revenue tripled since August to $150M annually
• Ant Group relaunches health AI as "Ant Afu" with 15M monthly users
• Both models show strong commercial viability for medical AI